Welcome to our dedicated page for Halozyme Therapeutics news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Therapeutics stock.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company headquartered in San Diego, CA, focused on developing and commercializing innovative oncology therapies. The company's core mission is to enhance the efficacy of cancer treatments by targeting the tumor microenvironment, particularly through its lead investigational drug, pegph20. This drug aims to improve the penetration of co-administered cancer therapies into solid tumors, potentially making existing treatments more effective.
Halozyme's proprietary ENHANZE® drug delivery technology platform has garnered significant attention and partnerships with leading pharmaceutical companies such as Roche, Pfizer, Janssen, Baxalta, AbbVie, and Lilly. This technology facilitates the subcutaneous administration of biologics and small molecule compounds that are traditionally delivered intravenously, potentially allowing for quicker and more convenient therapy delivery.
The company has built a strong foundation of value-driving partnerships and continues to innovate in drug-device combination products using advanced auto-injector technology to improve patient convenience, comfort, and adherence. Halozyme's commercial portfolio includes proprietary products like Hylenex® and XYOSTED®, and ongoing product development in partnership with pharmaceutical companies such as Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Recent achievements highlight Halozyme’s growth and innovation. Notably, the U.S. FDA approved Takeda’s HYQVIA®, co-formulated with ENHANZE®, for the maintenance therapy of chronic inflammatory demyelinating polyneuropathy (CIDP), underscoring the potential of Halozyme’s technology to enhance treatment efficacy. Another milestone includes the Japanese Ministry of Health's approval of argenx's VYVDURA® for generalized myasthenia gravis, demonstrating global expansion and acceptance of ENHANZE®-enabled treatments.
Financially, Halozyme continues to show robust growth. The company reported strong revenue and earnings growth in the first quarter of 2024, reaffirming its positive financial guidance for the year. Halozyme also announced a new $750 million share repurchase program, indicating confidence in sustained growth.
Halozyme's efforts in maintaining an extensive patent portfolio, including the recent grant of European Patent No. 4269578 for its ENHANZE® rHuPH20 product, further solidify its market position and prospects for long-term revenue durability. The company's strategic collaborations and commitment to innovative patient solutions make it a significant player in the biopharmaceutical industry.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced plans to release its first-quarter 2023 financial and operating results on May 9, 2023, after the trading day concludes. A conference call will follow at 4:30 p.m. ET to discuss the results, accessible via pre-registration.
The call will also be available as a live webcast on the company's website. Halozyme is focused on enhancing patient experiences through its innovative ENHANZE® technology, which improves the delivery of injected medications. As of now, it has impacted over 700,000 patients globally.
Halozyme partners with major pharmaceutical firms like Roche and Pfizer, and it has a range of commercial products, including XYOSTED®, TLANDO®, and NOCDURNA®.
Halozyme Therapeutics (NASDAQ: HALO) announced that the recent decision by the European Patent Office regarding a co-formulation patent for DARZALEX FASPRO® will not affect its U.S. and European royalty revenues through at least 2030. The company reaffirms its 2023 revenue guidance, estimating total revenue between $815 million and $845 million, and royalty revenue between $445 million and $455 million. Despite the revocation of the European Patent EP3370770B1, Halozyme expects to maintain royalty payments from Janssen. A written decision is forthcoming, and an appeal could suspend the decision temporarily.
Halozyme Therapeutics reported significant financial growth for Q4 2022, with revenues increasing by 78% year-over-year to $181 million, driven by record royalty revenues of $106 million. Full-year revenues rose to $660.1 million, a 49% increase compared to 2021. GAAP diluted earnings per share for the fourth quarter were $0.42, while non-GAAP EPS was $0.48. For 2023, Halozyme expects revenues between $815 million and $845 million, reflecting 23%-28% growth, and EBITDA of $415 million to $440 million, indicating over 30% growth. Ongoing regulatory approvals for ENHANZE® products are anticipated to bolster future performance.
Halozyme Therapeutics (NASDAQ: HALO) announced it will release its fourth quarter and full year 2022 financial results on February 21, 2023, after trading closes. A conference call will follow at 4:30 p.m. ET, accessible via pre-registration. The call will also be webcast live on Halozyme's website.
Halozyme focuses on improving patient experiences and outcomes through its ENHANZE® technology, facilitating drug delivery and reducing treatment burdens. The company has impacted over 600,000 patients globally with its products, partnering with major pharmaceutical firms.
Halozyme Therapeutics (NASDAQ: HALO) announced the appointment of Barbara Duncan to its Board of Directors on February 6, 2023. Ms. Duncan has over 25 years of experience in the biopharmaceutical industry, having served as CFO at Intercept Pharmaceuticals and held key positions at DOV Pharmaceutical and Lehman Brothers. Dr. Helen Torley, President and CEO, expressed confidence that Ms. Duncan’s financial expertise would contribute to the company's growth. Halozyme is known for its ENHANZE® technology, which improves drug delivery, having impacted over 600,000 patients globally.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plans to redeem all outstanding 1.25% convertible senior notes due 2024 on March 17, 2023. Holders can convert their notes at a rate of 42.0331 shares per $1,000 principal amount, equating to a conversion price of approximately $23.79 per share. Non-converted notes will be redeemed at 100% of their principal plus accrued interest. This action is part of the company's strategy to manage its debt effectively.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced robust financial guidance for 2023, projecting total revenues of $815 to $845 million, representing over 20% growth versus 2022. Recurring revenues from royalties are expected to exceed $445 million, marking a similar growth rate. The EBITDA is projected to rise by over 30%, reaching between $415 and $440 million. Non-GAAP diluted EPS guidance ranges from $2.50 to $2.65. The company anticipates two new commercial launches and significant growth in its ENHANZE pipeline.
FAQ
What is the current stock price of Halozyme Therapeutics (HALO)?
What is the market cap of Halozyme Therapeutics (HALO)?
What is Halozyme Therapeutics' main focus?
What is the ENHANZE® technology?
Who are Halozyme's key partners?
What recent approvals have Halozyme's technologies received?
What are some of Halozyme's proprietary products?
Where is Halozyme headquartered?
How does Halozyme's ENHANZE® technology benefit patients?
What is the significance of Halozyme's recent European patent grant?
What financial outlook did Halozyme recently provide?
What is pegph20?
